日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Burden of MASLD and liver fibrosis: evidence from Phenome India cohort

MASLD和肝纤维化的负担:来自印度表型组队列的证据

Arvind, Meghana; Verma, Anshul; K, Sreeshma Raj; Prakash, Satyartha; Kumar, Vignesh S; Uddin, Mohammad Azhar; Narayan, Ayushi; Rathore, Mamta; Rawat, Nancy; Sahu, Ankita; Kumar, Yogesh; Leuva, Pulkit Hasmukhbhai; Sharma, Monika; S, Rajesh; Saha, Dwaipayan; Mridha, Ankita; Nath, Ishant Jyoti; Hussain, Ashique; Rajkumari, Borsha; Thapa, Mamta; Kumari, Neha; S, Vishwapriya; Chatterjee, Shilpak; Ganguly, Dipyaman; Awasthi, Ashish; Yenamandra, Vamsi K; Singh, Ajay Pratap; Mishra, Aastha; Raychaudhuri, Swasti; Tallapaka, Karthik Bharadwaj; Chandak, Giriraj Ratan; Kulkarni, Mahesh J; Dharne, Mahesh S; Wahengbam, Romi; Subudhi, Umakanta; Biswas, Sagnik; Shalimar; Chaudhary, Kumardeep; Sengupta, Shantanu; Chakrabarti, Partha; Sardana, Viren

Early treatment outcome prediction in metastatic castration-resistant prostate cancer utilizing 3-month tumor growth rate (g-rate) based machine learning model

利用基于3个月肿瘤生长率(g-rate)的机器学习模型预测转移性去势抵抗性前列腺癌的早期治疗结果

Ugwueke, Esther C; Azzam, Mohamed; Zhou, Mengxi; Teply, Benjamin A; Bergan, Raymond C; Wan, Shibiao; Fojo, Antonio Tito; Leuva, Harshraj; Wang, Jieqiong

Abiraterone vs Enzalutamide Among US Veterans With Metastatic Hormone-Sensitive Prostate Cancer

阿比特龙与恩扎卢胺治疗美国退伍军人转移性激素敏感性前列腺癌的疗效比较

Leuva, Harshraj; Zhou, Mengxi; Teply, Benjamin A; Park, Yeun-Hee Anna; Luhrs, Carol; Mundi, Prabhjot Singh; Bates, Susan E; Faiena, Izak; Fojo, Tito; Schoen, Martin W

Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses

利用适用于真实世界分析的时间无关g率法评估奥拉帕尼对美国转移性前列腺癌退伍军人的疗效

Leuva, Harshraj; Zhou, Mengxi; Jamaleddine, Nader; Meseha, Mina; Faiena, Izak; Anna Park, Yeun-Hee; McWilliams, Glen; Luhrs, Carol; Maxwell, Kara N; Von Hoff, Daniel; Bates, Susan E; Fojo, Tito

Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia

重型再生障碍性贫血患者接受免疫抑制治疗后克隆演变和髓系肿瘤的预测因素

Groarke, Emma M; Patel, Bhavisha A; Shalhoub, Ruba; Gutierrez-Rodrigues, Fernanda; Desai, Parth; Leuva, Harshraj; Zaimoku, Yoshitaka; Paton, Casey; Spitofsky, Nina; Lotter, Jennifer; Rios, Olga; Childs, Richard W; Young, David J; Dulau-Florea, Alina; Dunbar, Cynthia E; Calvo, Katherine R; Wu, Colin O; Young, Neal S

Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans

癌症对 COVID-19 发病率、预后和疫苗有效性的影响:一项针对美国退伍军人的前瞻性队列研究

Leuva, Harshraj; Zhou, Mengxi; Brau, Norbert; Brown, Sheldon T; Mundi, Prabhjot; Rosenberg, Ta-Chueh Melody; Luhrs, Carol; Bates, Susan E; Park, Yeun-Hee Anna; Fojo, Tito

Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study

一项多中心、开放标签、随机研究的结果显示,使用干粉吸入器给药的格隆溴铵/福莫特罗治疗中重度慢性阻塞性肺疾病患者的疗效和安全性

Salvi, Sundeep; Kumar, Anand; Agrawal, Sumit; Leuva, Amritlal; Shukla, Vineet Kumar; Deshpande, Shrikant Vishnu; Balamurugan, Santhalingam; Singh, Ajit; Tikkiwal, Sharad; Gupta, Sandeep K; Singh, Bhanu Pratap; Lopez, Meena; Sawant, Sandesh; Vaidya, Abhijit; Gogtay, Jaideep

Rise of the phoenix: Mucormycosis in COVID-19 times

浴火重生:新冠疫情下的毛霉菌病

Ravani, Swati A; Agrawal, Garima A; Leuva, Parth A; Modi, Palak H; Amin, Krisha D

Response to comments on: Rise of the phoenix: Mucormycosis in COVID-19 times

对以下文章的评论回应:凤凰涅槃:新冠疫情时期的毛霉菌病

Ravani, Swati A; Agrawal, Garima A; Leuva, Parth A; Modi, Palak H; Amin, Krisha D

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

在再生障碍性贫血的标准免疫抑制方案中加入艾曲波帕

Townsley, Danielle M; Scheinberg, Phillip; Winkler, Thomas; Desmond, Ronan; Dumitriu, Bogdan; Rios, Olga; Weinstein, Barbara; Valdez, Janet; Lotter, Jennifer; Feng, Xingmin; Desierto, Marie; Leuva, Harshraj; Bevans, Margaret; Wu, Colin; Larochelle, Andre; Calvo, Katherine R; Dunbar, Cynthia E; Young, Neal S